Dec 30, 2008 - Northfield Laboratories Inc. announced today that the U.S. FDA has accepted for filing its Biologics License Application (BLA) for PolyHeme, the Company's investigative human hemoglobin-based red cell substitute for the treatment of life-threatening red blood cell loss when an oxygen-carrying fluid is required and red blood cells are not available.
The details can be read here.
No comments:
Post a Comment